TrialPhase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Trial details
- Registry ID
- NCT02912260
- Phase
- Phase 2
MDGL
Madrigal Pharmaceuticals, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
12Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Trial details
- Registry ID
- NCT03038022
- Phase
- Phase 2
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Trial details
- Registry ID
- NCT03900429
- Phase
- Phase 3
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
Trial details
- Registry ID
- NCT04197479
- Phase
- Phase 3
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Trial details
- Registry ID
- NCT04951219
- Phase
- Phase 3
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
Trial details
- Registry ID
- NCT05500222
- Phase
- Phase 3
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Trial details
- Registry ID
- NCT07335601
- Phase
- Phase 2
Latest recorded trial changes
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
NCT05500222 · Madrigal Pharmaceuticals, Inc.
Planned enrollment increased by 145 participants
− Before
700 participants (planned)
+ After
845 participants (planned)
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601 · Madrigal Pharmaceuticals, Inc.
Primary completion date changed
− Before
Jul 2027
+ After
Aug 2028
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219 · Madrigal Pharmaceuticals, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
1000 participants (planned)
+ After
810 participants (actual)
Primary completion date changed
− Before
Mar 2026
+ After
Mar 2027
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601 · Madrigal Pharmaceuticals, Inc.
Recruitment status changed
− Before
Active not recruiting
+ After
Recruiting
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
NCT02912260 · Madrigal Pharmaceuticals, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Change from baseline in hepatic fat fraction assessed by MRI-PDFF
+ After
Measure: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)
Primary completion date changed
− Before
Oct 2017
+ After
25 Oct 2017
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT03038022 · Madrigal Pharmaceuticals, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Mean Percentage Change in LDL-C From Baseline To Week 12
+ After
Measure: Mean Percent Change in LDL-C From Baseline To Week 12
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT03038022 · Madrigal Pharmaceuticals, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C)
+ After
Measure: Mean Percentage Change in LDL-C From Baseline To Week 12
Primary completion date changed
− Before
18 Dec 2017
+ After
15 Jan 2018